STOCK TITAN
  1. Home
  2. Sec-filings
  3. NSRX
  4. [6-K] Nasus Pharma Ltd Current Report (Foreign Issuer)

Nasus Pharma (NYSE American: NSRX) taps Brendan O’Grady to lead next phase

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Nasus Pharma Ltd. appointed Brendan P. O’Grady as Chief Executive Officer, effective July 27, 2026, following a mutual separation agreement with former CEO and director Dan Teleman, whose resignation was described as not stemming from any disagreement over operations, policies or practices.

The board also appointed Mr. O’Grady as a Class III director, with a term running until the 2028 annual general meeting, and approved a compensation package that still requires shareholder approval. He is expected to enter into the company’s standard indemnification and exemption agreement. Nasus highlighted Mr. O’Grady’s three decades of global pharma leadership and stated that he will focus on unlocking the commercial potential of lead intranasal epinephrine candidate NS002, advancing the pipeline and business development, and maximizing the Nasax intranasal technology platform. The company referenced plans to move NS002 toward a pivotal trial in the fourth quarter of 2026 with topline data in the first quarter of 2027 and cited a $2 billion anaphylaxis treatment market opportunity. An updated corporate presentation was also made available.

Positive

  • None.

Negative

  • None.
NS002 market opportunity $2 billion Stated potential market size for anaphylaxis treatment candidate NS002
Industry experience 35 years Brendan P. O’Grady’s pharmaceutical leadership experience cited by the company
Tenure at Teva 21 years Years Brendan P. O’Grady spent in commercial roles at Teva Pharmaceuticals
Board term end year 2028 Class III directorship term ending at the 2028 annual general meeting
Report of Foreign Private Issuer regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER pursuant to Rule 13a-16"
A report of a foreign private issuer is a formal filing that a non‑U.S. company makes to U.S. regulators to share important business, financial, or governance information with American investors. Think of it as a regular update or press packet that keeps investors informed about events that could change a company’s value—like earnings, management changes, contracts, or regulatory developments—so investors can make timely, informed decisions.
mutual separation agreement regulatory
"the Company entered into a mutual separation agreement with Mr. Dan Teleman"
pivotal trial medical
"advance NS002 toward a pivotal trial in the fourth quarter of 2026"
A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.
topline data readout medical
"pivotal trial in the fourth quarter of 2026 and topline data readout the first quarter of 2027"
A topline data readout is the initial summary of a clinical trial’s most important results, showing whether the study met its main goals. Like a headline score after a sports game, it gives investors a quick sense of success or failure that can shift a company’s outlook, affect future funding, and move the stock while more detailed analyses and regulatory reviews follow.
intranasal epinephrine medical
"lead product candidate, NS002, is being developed as an intranasal epinephrine treatment"
Type I allergic reactions medical
"intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis"
Type I allergic reactions are immediate, often rapid immune overreactions in which the body’s defense system mistakes a harmless substance (like a drug, food, or insect sting) for a threat and releases chemicals that cause symptoms from hives and swelling to life‑threatening anaphylaxis. Like a smoke alarm that blares at burnt toast, these reactions can halt clinical trials, trigger safety warnings or product recalls, and influence regulatory decisions, liability exposure, and demand for treatments—making them important to investors evaluating health‑care and consumer product risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

Who was appointed CEO of Nasus Pharma (NSRX) and when is the change effective?
Nasus Pharma appointed Brendan P. O’Grady as Chief Executive Officer, with the leadership transition effective July 27, 2026. He also joins the board as a Class III director, serving until the company’s 2028 annual general meeting of shareholders.

What happened to former Nasus Pharma (NSRX) CEO Dan Teleman and was there any disagreement?
Nasus Pharma entered a mutual separation agreement with former CEO and director Dan Teleman, effective July 22, 2026. The company states his resignation was not related to any disagreement regarding operations, policies or practices, and he will assist during a contractual notice period.

What is Nasus Pharma’s NS002 program and its expected clinical timeline?
NS002 is Nasus Pharma’s lead intranasal epinephrine candidate for Type I allergic reactions, including anaphylaxis. The company cites plans to advance NS002 toward a pivotal trial in Q4 2026 with topline data readout in Q1 2027, supporting pre-commercial planning.

How large is the market opportunity Nasus Pharma (NSRX) sees for NS002?
Nasus Pharma describes NS002 as targeting a $2 billion anaphylaxis treatment market opportunity. The company notes that NS002’s rapid-onset intranasal administration could offer an alternative in a market currently dominated by injectable treatments for severe allergic reactions.

What other updates did Nasus Pharma (NSRX) provide alongside the CEO appointment?
Nasus Pharma made an updated corporate presentation available on its website, attached as an exhibit. It also noted that most of the report, excluding specified press-release paragraphs and the presentation, is incorporated by reference into its Form S-8 registration statement.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2026

 

Commission File Number: 001-42796

 

Nasus Pharma Ltd.

 

P.O. Box 284

Tel Aviv, Israel 6100201

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

CONTENTS

 

Appointment of Chief Executive Officer

 

On July 27, 2026, Nasus Pharma Ltd. (the “Company”) appointed Mr. Brendan P. O’Grady to serve as the Company’s Chief Executive Officer (“CEO”). In connection with Mr. O’Grady’s appointment as CEO, Nasus Pharma Inc. entered into an employment agreement with Mr. O’Grady, dated as of July 27, 2026. Mr. O’Grady’s employment with the Company commences immediately.

 

Prior to joining the Company, from May 2024 to October 2025, Mr. O’Grady served as Chief Executive Officer of Assertio Holdings, Inc. (Nasdaq: ASRT). From June 2022 to February 2024, Mr. O’Grady served as Chief Executive Officer of the Global Formulations Business at Glenmark Pharmaceuticals Ltd. (NSE: GLENMARK). Prior to that, from August 2021 to June 2022, Mr. O’Grady served as Chief Growth and Commercial Officer of American Well Corporation (NYSE: AMWL). Between 2001 and 2021, Mr. O’Grady held various positions at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), most recently serving as Chief Executive Officer and President of Teva USA and Executive Vice President, North America Commercial. Earlier in his career, Mr. O’Grady held various positions at Sanofi S.A. (Nasdaq: SNY). Mr. O’Grady holds a Bachelor of Science degree in Management Science, with a concentration in Marketing, from the State University of New York and a Master of Business Administration degree from Baker University.

 

On July 28, 2026, the Company issued a press release titled “Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O’Grady as Chief Executive Officer to Lead Strategic Growth,” a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

 

Departure of Chief Executive Officer

 

On July 24, 2026, the Company’s entered into a mutual separation agreement with Mr. Dan Teleman, pursuant to which he agreed to resign from his position of Chief Executive Officer of the Company and from the Company’s Board of Directors, effective July 22, 2026. Mr. Teleman’s employment with the Company will continue through the expiration of the contractual notice period provided under his employment agreement. During such period, Mr. Teleman will not perform his day-to-day responsibilities but will remain reasonably available to assist with the transition to the incoming Chief Executive Officer and provide consultation as reasonably requested by the Chairman of the Company’s Board of Directors or the Company’s Board of Directors. Mr. Teleman’s resignation was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.

 

The Company’s Board of Directors appointed Mr. O’Grady to fill the vacancy on the Board of Directors as a result of Mr. Teleman’s resignation and will serve as a Class III director until the Company’s 2028 annual general meeting of shareholders. In addition, Mr. O’Grady’s compensation package was approved by the Board of Directors, and remains subject to the approval of the Company’s shareholders. In connection with this appointment, the Company expects to enter into its standard form of indemnification and exemption agreement with Mr. O’Grady on the same terms as the indemnification and exemption agreements previously entered into between the Company and each of its directors and executive officers. There are no related party transactions involving Mr. O’Grady required to be disclosed under Item 7.B of Form 20-F.

 

Corporate Presentation

 

On July 28, 2026, the Company made available an updated corporate presentation on its website. A copy of the corporate presentation is attached hereto as Exhibit 99.2 to this Report of Foreign Private Issuer on Form 6-K.

 

Incorporation by Reference

 

This Report of Foreign Private Issuer on Form 6-K (excluding (i) the second, third and fourth paragraphs of the press release included as Exhibit 99.1 hereto and (ii) Exhibit 99.2) is incorporated by reference into the Company’s Registration Statement on Form S-8 (File No. 333-296252), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press Release dated July 28, 2026 titled “Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O’Grady as Chief Executive Officer to Lead Strategic Growth”
99.2   Corporate Presentation, dated July 2026

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NASUS PHARMA LTD.
     
Date: July 28, 2026 By: /s/ Eyal Rubin
  Name: Eyal Rubin
  Title: Chief Financial Officer

 

3

 

 

 

Exhibit 99.1

 

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O’Grady as Chief Executive Officer to Lead Strategic Growth

 

TEL AVIV, Israel, July 28, 2026 – Nasus Pharma Ltd. (Nasdaq: NSRX) (“Nasus”, “Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the appointment of pharma industry veteran Brendan P. O’Grady as its Chief Executive Officer. Mr. O’Grady will lead the Company’s next phase of growth, with an initial focus on unlocking the commercial potential of NS002, advancing the Company’s pipeline and business development initiatives, and maximizing the value of its proprietary Nasax® intranasal technology platform. Mr. O’Grady succeeds Dan Teleman, with the leadership transition effective July 27, 2026.

 

“Brendan’s appointment reflects the Board’s commitment to advance Nasus to its next phase of growth, and represents a significant milestone in the Company’s evolution,” said Udi Gilboa, Chairman of the Board of Directors of Nasus Pharma. “As we advance NS002 toward a pivotal trial in the fourth quarter of 2026 and topline data readout the first quarter of 2027, our strategic focus is increasingly centered on pre-commercial planning. Brendan brings strategic vision, extensive experience in payors and reimbursement, and proven commercial leadership required to develop and execute this strategy. We are delighted to welcome Brendan to the Nasus team.”

 

“On behalf of the Board of Directors, I also extend our thanks to Dan Teleman for his service and many contributions to Nasus, and wish him continued success in his future endeavors,” concluded Mr. Gilboa.

 

“I am thrilled to be joining Nasus at such an important stage in the Company’s development,” said Mr. O’Grady. “NS002 presents an opportunity to address a significant unmet medical need in the treatment of anaphylaxis and represents a growing $2 billion market opportunity. In a market currently dominated by injectables, NS002’s rapid onset and intranasal administration offer patients and caregivers a potentially superior alternative for treating severe allergic reactions. Based on my 35 years of experience leading commercial strategy and go-to-market programs, I believe the Nasus portfolio represents a significant value generation opportunity, and I look forward to working with the entire Nasus leadership team to deliver the therapeutic promise of these assets to patients in need.”

 

Mr. O’Grady is a highly accomplished pharmaceutical executive with more than three decades of global leadership experience spanning corporate strategy, business development, commercialization, market access, strategic partnerships and global product launches. Mr. O’Grady has led multi-billion-dollar pharmaceutical businesses, developed and executed global commercialization strategies, established strategic pharmaceutical partnerships, and consistently created shareholder value across publicly traded healthcare companies. He spent 21 years at Teva Pharmaceuticals in a variety of commercial roles, rising to CEO of Teva USA and EVP North America Commercial while scaling profitability, growth, and productivity. He has also served as Chief Executive Officer of Assertio Holdings (Nasdaq: ASRT). Mr. O’Grady has served on a variety of public and private corporate boards and advisory committees. Most notably, he served as a director of the telehealth company, American Well Corporation (Amwell), from 2015 - 2021. While on the board of Amwell, he served as the compensation committee chair and as a member of the IPO committee. He also served with distinction as a member of the United States Department of Commerce, U.S. Investment Advisory Council from August 2019 through June of 2021. Mr. O’Grady holds a Bachelor of Science degree in Management Science from SUNY Geneseo (Geneseo State University, Geneseo, NY) and a Master of Business Administration from Baker University’s (Baldwin City, Kansas) School of Professional and Graduate Studies.

 

Additional information regarding Mr. O’Grady’s appointment will be furnished by the Company in a Report on Form 6-K with the U.S. Securities and Exchange Commission.

 

 

 

 

About Nasus Pharma

 

Nasus Pharma Ltd. (Nasdaq: NSRX) is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary intranasal powder technology platform. The Company’s lead product candidate, NS002, is being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis. In addition to NS002, Nasus is leveraging its proprietary technology platform to develop a growing pipeline of differentiated intranasal product candidates designed to provide rapid, reliable and patient-friendly drug delivery across multiple therapeutic areas.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward looking statements. For example, Nasus Pharma is using forward looking statements in this press release when it discusses: statements regarding the Company’s strategy to commercialize NS002 and unlocking its commercial potential; advancing the Company’s pipeline and future business development initiatives, maximizing the value of its proprietary Nasax intranasal technology platform; the next phase of Nasus Pharma’s growth; the Company advancing NS002 toward a pivotal trial in the fourth quarter of 2026 and topline data readout the first quarter of 2027; the increasing strategic focus on pre-commercial planning; the opportunity NS002 presents to address a significant unmet medical need; the believe that the Nasus portfolio represents a significant value generation opportunity; and the potential applications and promise of the Company’s proprietary intranasal technology platform. These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to update or revise these forward-looking statements except as required by applicable law.

 

Company Contact

 

Nasus Pharma Ltd.

info@nasuspharma.com

 

Investor Contact

 

Mike Moyer

LifeSci Advisors

+1-617-308-4306

mmoyer@lifesciadvisors.com

 

 

 

 

 

Exhibit 99.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

46 documents

Press Releases